Aclarion Implements 1-for-370 Reverse Stock Split to Maintain Nasdaq Listing

Healthcare technology company Aclarion (Nasdaq: ACON) has announced a 1-for-370 reverse stock split of its common stock, effective January 29, 2025, in a strategic move to maintain its Nasdaq listing status. The decision comes as the company aims to meet Nasdaq's minimum bid price requirement of $1.00 per share.

The reverse split, approved by stockholders on December 31, 2024, will dramatically reduce Aclarion's outstanding shares from approximately 185 million to 500,000. This corporate action represents a significant restructuring of the company's stock, with potential implications for market liquidity and investor perception.

For shareholders, the consolidation means every 370 shares will be automatically combined into one share, with fractional shares rounded up to the nearest whole share. The company's outstanding warrants, stock options, and restricted stock units will be proportionally adjusted, maintaining their relative value.

The move highlights the challenges faced by smaller publicly traded healthcare technology companies in maintaining their Nasdaq listings. While reverse splits don't directly affect a company's market value, they can help maintain institutional investor interest and market accessibility by keeping share prices above critical thresholds.

Aclarion, which specializes in chronic low back pain diagnosis through its Nociscan platform, will continue trading under the same ticker symbol, though with a new CUSIP number. The maintenance of its Nasdaq listing is crucial for the company's visibility and access to capital markets as it continues to develop its healthcare technology solutions.